
    
      This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study. This
      study is designed to determine whether treatment with ALLN-177 for 28 days can reduce urinary
      oxalate excretion in patients with enteric hyperoxaluria and to evaluate the safety of
      ALLN-177 in this patient population compared to placebo.
    
  